BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30256836)

  • 1. Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis.
    Wetmore JB; Li S; Yan H; Xu H; Peng Y; Sinsakul MV; Liu J; Gilbertson DT
    PLoS One; 2018; 13(9):e0203767. PubMed ID: 30256836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative mortality risk of anemia management practices in incident hemodialysis patients.
    Brookhart MA; Schneeweiss S; Avorn J; Bradbury BD; Liu J; Winkelmayer WC
    JAMA; 2010 Mar; 303(9):857-64. PubMed ID: 20197532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study.
    Akizawa T; Tsubakihara Y; Hirakata H; Watanabe Y; Hase H; Nishi S; Babazono T; Kumagai M; Katakura S; Uemura Y; Ohashi Y;
    Clin Exp Nephrol; 2016 Dec; 20(6):885-895. PubMed ID: 26779906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
    Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
    Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Safety of Long-Acting vs. Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis.
    Desai R; Unigwe I; Riaz M; Smith SM; Shukla AM; Mohandas R; Jeon N; Park H
    Clin Pharmacol Ther; 2024 Jul; 116(1):217-224. PubMed ID: 38629679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients.
    Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2014 Oct; 18(5):404-13. PubMed ID: 24571446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients.
    Evans M; Carrero JJ; Bellocco R; Barany P; Qureshi AR; Seeberger A; Jacobson SH; Hylander-Rössner B; Rotnitzky A; Sjölander A
    Nephrol Dial Transplant; 2017 Nov; 32(11):1892-1901. PubMed ID: 27672090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agents: dose and mortality risk.
    Bellinghieri G; Condemi CG; Saitta S; Trifirò G; Gangemi S; Savica V; Buemi M; Santoro D
    J Ren Nutr; 2015 Mar; 25(2):164-8. PubMed ID: 25529282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study.
    Martínez-Castelao A; Cases A; Carballada AT; Iranzo JT; Bronsoms J; Vallès-Prats M; Monserrat DT; Jimenez EM;
    Nefrologia; 2015; 35(2):179-88. PubMed ID: 26300512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.
    Kwon O; Jang HM; Jung HY; Kim YS; Kang SW; Yang CW; Kim NH; Choi JY; Cho JH; Kim CD; Kim YL; Park SH;
    PLoS One; 2015; 10(10):e0140241. PubMed ID: 26452232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis.
    Rheault MN; Molony JT; Nevins T; Herzog CA; Chavers BM
    Kidney Int; 2017 Jan; 91(1):177-182. PubMed ID: 27865440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfusion burden among patients with chronic kidney disease and anemia.
    Lawler EV; Bradbury BD; Fonda JR; Gaziano JM; Gagnon DR
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):667-72. PubMed ID: 20299366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study.
    Portolés JM; de Francisco AL; Górriz JL; Martínez-Castelao A; López-Gómez JM; Arias M; de la Cruz JJ; Cases A; Fernández E; Aljama P
    Kidney Int Suppl; 2008 Dec; (111):S82-7. PubMed ID: 19034334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.
    Seliger S; Fox KM; Gandra SR; Bradbury B; Hsu VD; Walker L; Chiou CF; Fink JC
    Clin J Am Soc Nephrol; 2010 May; 5(5):882-8. PubMed ID: 20299377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.